Brief Title: Paracervical Block for Postoperative Pain After Transcervical Procedures Under TIVA

November 11, 2026 updated by: Zeenat Usman, Shaheed Zulfiqar Ali Bhutto Medical University

EFFECTIVENESS OF PARACERVICAL BLOCK IN ADDITION TO STANDARD ANALGESIA FOR POSTOPERATIVE PAIN CONTROL FOLLOWING TRANSCERVICAL UTERINE PROCEDURES UNDER TIVA: A RANDOMIZED CONTROLLED TRIAL

Paracervical Block for Postoperative Pain After Transcervical Procedures Under TIVA

Study Overview

Detailed Description

EFFECTIVENESS OF PARACERVICAL BLOCK IN ADDITION TO STANDARD ANALGESIA FOR POSTOPERATIVE PAIN CONTROL FOLLOWING TRANSCERVICAL UTERINE PROCEDURES UNDER TIVA: A RANDOMIZED CONTROLLED TRIAL

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Zeenat Usman, MS obstetrics and Gyanecology
  • Phone Number: +923315333910
  • Email: usmanbut2@gmail.com

Study Contact Backup

Study Locations

    • Islamabad
      • Islamabad, Islamabad, Pakistan, 04485
        • Pakistan Institute of Medical Sciences (PIMS)
        • Contact:
        • Contact:
        • Principal Investigator:
          • Zeenat Usman, MS obstetrics and gyane
        • Sub-Investigator:
          • Quratulain Saeed, FCPS - Obstetrics and Gynaecol
        • Sub-Investigator:
          • Tooba Batool

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women aged 18 years or older.
  • Women scheduled to undergo an eligible transcervical uterine procedure under total intravenous anaesthesia (TIVA).
  • Women with stable haemodynamic condition before surgery.

Exclusion Criteria:

  • Known allergy or hypersensitivity to lidocaine or other planned local anaesthetic.
  • Significant hepatic disease affecting local anaesthetic metabolism.
  • Chronic opioid use or chronic pain requiring regular analgesic therapy.
  • Major intraoperative complication requiring deviation from the standardized anaesthetic or surgical protocol.
  • Patients requiring emergency surgery where informed consent or standardized study procedures cannot safely be completed.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Paracervical Block Plus Standard Analgesia

Participants will receive a standardized paracervical block using lidocaine in addition to standard total intravenous anesthesia (TIVA) and perioperative analgesia for eligible transcervical uterine procedures. Postoperative pain scores and analgesic requirements will be assessed and compared with the control group.

A standardized paracervical block will be administered after induction of total intravenous anesthesia (TIVA) and before uterine manipulation. The technique will use 2% lidocaine without adrenaline, with 1 mL injected at each of four cervical positions (2, 4, 8, and 10 o'clock), for a total volume of 4 mL (80 mg lidocaine). Aspiration will be performed before and during injection to reduce the risk of intravascular administration. The block will be given in addition to standard TIVA and perioperative analgesia for eligible transcervical uterine procedures.

No Intervention: Standard Analgesia Alone

Participants will receive standard total intravenous anesthesia (TIVA) and perioperative analgesia for eligible transcervical uterine procedures without a paracervical block. Postoperative pain scores and analgesic requirements will be assessed and compared with the intervention group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative Pain Score (0-10 Visual Analogue Scale [VAS] Score)
Time Frame: From arrival in the recovery area (when awake and able to communicate) to 4 hours post-procedure, assessed at recovery arrival, 30 minutes, 1 hour, 2 hours, and 4 hours where feasible.

Postoperative pain intensity will be measured using a 0-10 Visual Analogue Scale (VAS), with 0 representing no pain and 10 representing the worst imaginable pain. The VAS score will be recorded for each participant at recovery room arrival (when awake and able to communicate), 30 minutes, 1 hour, 2 hours, and 4 hours after the procedure, where feasible. The mean or median postoperative pain scores will be compared between participants receiving paracervical block plus standard analgesia and those receiving standard analgesia alone.

From arrival in the recovery area (when awake and able to communicate) to 4 hours post-procedure, assessed at recovery arrival, 30 minutes, 1 hour, 2 hours, and 4 hours where feasible.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Participants Requiring Rescue Analgesia (%)
Time Frame: From completion of the procedure until 4 hours post-procedure.

The proportion of participants requiring additional rescue analgesia for postoperative pain despite receiving standard perioperative analgesia will be recorded. Rescue analgesia requirement will be assessed as a binary outcome (Yes/No) using the study Case Report Form (CRF). The percentage of participants requiring rescue analgesia will be compared between the intervention and control groups.Control group is the one receiving standard analgesia that is only TIVA and case group is standard analgesia that is TIVA and paracervical block group

From completion of the procedure until 4 hours post-procedure.
Time to First Rescue Analgesia (Minutes)
Time Frame: From completion of the procedure until 4 hours post-procedure

Time to first rescue analgesia will be measured in minutes from completion of the transcervical uterine procedure to administration of the first rescue analgesic. The time of administration will be documented using the medication administration record and structured Case Report Form (CRF), and compared between the two study groups.

From completion of the procedure until 4 hours post-procedure
Total Postoperative Rescue Analgesic Requirement (Drug-Specific Dose)
Time Frame: From completion of the procedure until 4 hours post-procedure.

The total dose of additional rescue analgesic medication administered to each participant for postoperative pain will be recorded using the medication administration record and structured Case Report Form (CRF). The drug name, individual dose and total dose administered during the postoperative observation period will be documented and compared between the two study groups. Results will be expressed in the appropriate drug-specific dose units (e.g., milligrams).

From completion of the procedure until 4 hours post-procedure.
Patient Satisfaction Score with Postoperative Pain Management (5-Point Likert Scale)
Time Frame: At the end of the postoperative recovery observation period, up to 4 hours after the procedure.

Participant satisfaction with postoperative pain management will be assessed using a predefined 5-point Likert scale recorded on the structured Case Report Form (CRF). The scale ranges from 1 (very dissatisfied), 2 (dissatisfied), 3 (neutral), 4 (satisfied), to 5 (very satisfied). Individual satisfaction scores will be recorded and compared between the two study groups.

At the end of the postoperative recovery observation period, up to 4 hours after the procedure.
Time to First Mobilization (Minutes)
Time Frame: From completion of the procedure until first mobilization or discharge from the recovery area, whichever occurs first, within 4 hours post-procedure.

Time to first mobilization will be measured in minutes from completion of the transcervical uterine procedure to the participant's first mobilization. The time will be recorded using the structured Case Report Form (CRF) and compared between participants receiving paracervical block plus standard analgesia and those receiving standard analgesia alone.

From completion of the procedure until first mobilization or discharge from the recovery area, whichever occurs first, within 4 hours post-procedure.
Incidence of Postoperative Nausea and Vomiting (Number and Percentage of Participants)
Time Frame: From arrival in the recovery area until 4 hours after completion of the procedure.

The incidence of postoperative nausea and vomiting will be assessed by recording the presence or absence of nausea and vomiting (Yes/No) using the structured Case Report Form (CRF). The requirement for rescue antiemetic medication will also be documented as Yes or No. Results will be expressed as the number and percentage of participants experiencing nausea and vomiting in each study group.

From arrival in the recovery area until 4 hours after completion of the procedure.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Zeenat Usman, MS obstetrics and Gyanecology, SZABMU,PIMS

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

April 30, 2027

Study Completion (Estimated)

June 30, 2027

Study Registration Dates

First Submitted

October 24, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data collected during this study will not be shared publicly or made available to external researchers. Data will be used by the study investigators for the purposes of the approved research. Participant confidentiality will be maintained in accordance with institutional ethical requirements.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe